9 research outputs found
ΠΠ°ΡΠ΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°ΡΠΈΡ ΠΈ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΉ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΠΉ ΡΡΠΎΠΌΠ±ΠΎΠ· Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΡΠ°Ρ ΠΈΡΠΎΡΠΌΠΎΠΉ ΡΠΈΠ±ΡΠΈΠ»Π»ΡΡΠΈΠΈ ΠΏΡΠ΅Π΄ΡΠ΅ΡΠ΄ΠΈΠΉ, ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠ΅Π³ΠΎ COVID-19 ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ
We present a case of cardiomyopathy with a reduced left ventricular ejection fraction of up to 18%, multivessel arterial thrombosis in a patient who had undergone severe COVID-19 3.5 months earlier. The cardiopathy was initially considered as an outcome of SARSCoV2-induced myocarditis, but MRI with delayed gadolinium contrast revealed no fibrosis or evidence of active myocarditis. A detailed collection of the medical history showed that the duration of tachyform atrial fibrillation exceeded the 4 months indicated in the medical records. Oligosymptomatic manifestation of arrhythmia occurred 8 months earlier, the patient did not consult a physician due to epidemic conditions. Coronary angiography revealed subtotal stenosis of the anterior descending artery. Most probably, the cardiopathy was arrhythmogenic and ischemic. After achieving normosystole and coronary stenting, the left ventricular ejection fraction was 25-27%. At the first hospitalization 4 months ago, left atrial auricular thrombus was detected. After COVID-19 the patient received inadequately low dose of apixaban 5 mg per day. Three weeks after COVID-19, the patient was diagnosed with infarction of the right kidney, wall thrombosis in the abdominal aorta, thrombosis of the superficial femoral, deep femoral, popliteal, anterior tibial arteries on the left, right popliteal artery; thrombotic complications could have developed both in situ and as a result of cardioembolism. Administration of dabigatran 300 mg per day and aspirin helped to dissolve the thrombus in the left atrial auricle, improve the course of intermittent claudication, and avoid recurrent thrombotic complications. COVID-19 could contribute to the progression of atherosclerosis, more malignant course of atrial fibrillation, development of thrombosis, but coronavirus infection is not the only cause of severe disease in a patient. Π‘OVID-19 can not only be the cause of direct lesions of the heart and vessels, but also have an indirect negative effect - to delay the detection of cardiac pathology and be the cause of its hypodiagnosis under the mask of βpostcovidβ.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΡΠ»ΡΡΠ°ΠΉ ΠΊΠ°ΡΠ΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΈ ΡΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠ°ΠΊΡΠΈΠΈ Π²ΡΠ±ΡΠΎΡΠ° Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠ° Π΄ΠΎ 18%, ΠΌΠ½ΠΎΠ³ΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΠΌ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠΌ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°, ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠ΅Π³ΠΎ COVID-19 ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ 3,5 ΠΌΠ΅Ρ. Π½Π°Π·Π°Π΄. ΠΠ·Π½Π°ΡΠ°Π»ΡΠ½ΠΎ ΠΊΠ°ΡΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡ ΡΠ°ΡΡΠ΅Π½ΠΈΠ²Π°Π»Π°ΡΡ ΠΊΠ°ΠΊ ΠΈΡΡ
ΠΎΠ΄ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΡΠ°, Π²ΡΠ·Π²Π°Π½Π½ΠΎΠ³ΠΎ SARS-CoV2, ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΠ Π’ Ρ ΠΎΡΡΡΠΎΡΠ΅Π½Π½ΡΠΌ ΠΊΠΎΠ½ΡΡΠ°ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π³Π°Π΄ΠΎΠ»ΠΈΠ½ΠΈΠ΅ΠΌ Π½Π΅ Π²ΡΡΠ²ΠΈΠ»Π° Π½ΠΈ ΡΠΈΠ±ΡΠΎΠ·Π°, Π½ΠΈ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΡΠ°. ΠΠΎΠ΄ΡΠΎΠ±Π½ΡΠΉ ΡΠ±ΠΎΡ Π°Π½Π°ΠΌΠ½Π΅Π·Π° ΠΏΠΎΠΊΠ°Π·Π°Π», ΡΡΠΎ Π΄Π°Π²Π½ΠΎΡΡΡ ΡΠ°Ρ
ΠΈΡΠΎΡΠΌΡ ΡΠΈΠ±ΡΠΈΠ»Π»ΡΡΠΈΠΈ ΠΏΡΠ΅Π΄ΡΠ΅ΡΠ΄ΠΈΠΉ ΠΏΡΠ΅Π²ΡΡΠ°Π΅Ρ 4 ΠΌΠ΅Ρ., ΡΠΊΠ°Π·Π°Π½Π½ΡΠ΅ Π² ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ. ΠΠ°Π»ΠΎΡΠΈΠΌΠΏΡΠΎΠΌΠ½Π°Ρ ΠΌΠ°Π½ΠΈΡΠ΅ΡΡΠ°ΡΠΈΡ Π°ΡΠΈΡΠΌΠΈΠΈ ΠΏΡΠΎΠΈΠ·ΠΎΡΠ»Π° Π½Π° 8 ΠΌΠ΅Ρ. ΡΠ°Π½ΡΡΠ΅, ΠΏΠ°ΡΠΈΠ΅Π½Ρ Π½Π΅ ΠΎΠ±ΡΠ°ΡΠ°Π»ΡΡ ΠΊ Π²ΡΠ°ΡΡ Π² ΡΠ²ΡΠ·ΠΈ Ρ ΡΠΏΠΈΠ΄ΠΎΠ±ΡΡΠ°Π½ΠΎΠ²ΠΊΠΎΠΉ. ΠΠΎ Π΄Π°Π½Π½ΡΠΌ ΠΊΠΎΡΠΎΠ½Π°ΡΠΎΠ°Π½Π³ΠΈΠΎΠ³ΡΠ°ΡΠΈΠΈ Π±ΡΠ» Π²ΡΡΠ²Π»Π΅Π½ ΡΡΠ±ΡΠΎΡΠ°Π»ΡΠ½ΡΠΉ ΡΡΠ΅Π½ΠΎΠ· ΠΏΠ΅ΡΠ΅Π΄Π½Π΅ΠΉ Π½ΠΈΡΡ
ΠΎΠ΄ΡΡΠ΅ΠΉ Π°ΡΡΠ΅ΡΠΈΠΈ. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²Π΅ΡΠΎΡΡΠ½ΠΎ, ΠΊΠ°ΡΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡ Π½ΠΎΡΠΈΡ Π°ΡΠΈΡΠΌΠΎΠ³Π΅Π½Π½ΡΠΉ ΠΈ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ Ρ
Π°ΡΠ°ΠΊΡΠ΅Ρ. ΠΠΎΡΠ»Π΅ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ Π½ΠΎΡΠΌΠΎΡΠΈΡΡΠΎΠ»ΠΈΠΈ ΠΈ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΡΠ°ΠΊΡΠΈΡ Π²ΡΠ±ΡΠΎΡΠ° Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠ° ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 25β27%. ΠΡΠΈ ΠΏΠ΅ΡΠ²ΠΎΠΉ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ 4 ΠΌΠ΅Ρ. Π½Π°Π·Π°Π΄ Π²ΡΡΠ²Π»Π΅Π½ ΡΡΠΎΠΌΠ± ΡΡΠΊΠ° Π»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ΅Π΄ΡΠ΅ΡΠ΄ΠΈΡ. ΠΠΎΡΠ»Π΅ COVID-19 ΠΏΠ°ΡΠΈΠ΅Π½Ρ ΠΏΠΎΠ»ΡΡΠ°Π» Π½Π΅Π°Π΄Π΅ΠΊΠ²Π°ΡΠ½ΠΎ Π½ΠΈΠ·ΠΊΡΡ Π΄ΠΎΠ·Ρ Π°ΠΏΠΈΠΊΡΠ°Π±Π°Π½Π° 5 ΠΌΠ³ Π² ΡΡΡΠΊΠΈ. Π§Π΅ΡΠ΅Π· 3 Π½Π΅Π΄. ΠΏΠΎΡΠ»Π΅ COVID-19 Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π±ΡΠ» Π²ΡΡΠ²Π»Π΅Π½ ΠΈΠ½ΡΠ°ΡΠΊΡ ΠΏΡΠ°Π²ΠΎΠΉ ΠΏΠΎΡΠΊΠΈ, ΠΏΡΠΈΡΡΠ΅Π½ΠΎΡΠ½ΡΠ΅ ΡΡΠΎΠΌΠ±Ρ Π² Π±ΡΡΡΠ½ΠΎΠΉ Π°ΠΎΡΡΠ΅, ΡΡΠΎΠΌΠ±ΠΎΠ· ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠ½ΠΎΠΉ Π±Π΅Π΄ΡΠ΅Π½Π½ΠΎΠΉ, Π³Π»ΡΠ±ΠΎΠΊΠΎΠΉ Π±Π΅Π΄ΡΠ΅Π½Π½ΠΎΠΉ, ΠΏΠΎΠ΄ΠΊΠΎΠ»Π΅Π½Π½ΠΎΠΉ, ΠΏΠ΅ΡΠ΅Π΄Π½Π΅ΠΉ Π±ΠΎΠ»ΡΡΠ΅Π±Π΅ΡΡΠΎΠ²ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠΉ ΡΠ»Π΅Π²Π°, ΠΏΠΎΠ΄ΠΊΠΎΠ»Π΅Π½Π½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠΈ ΡΠΏΡΠ°Π²Π°; ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ ΠΌΠΎΠ³Π»ΠΈ ΡΠ°Π·Π²ΠΈΡΡΡΡ ΠΊΠ°ΠΊ in situ, ΡΠ°ΠΊ ΠΈ Π±ΡΡΡ ΡΠ»Π΅Π΄ΡΡΠ²ΠΈΠ΅ΠΌ ΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΌΠ±ΠΎΠ»ΠΈΠΈ. ΠΠ°Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π΄Π°Π±ΠΈΠ³Π°ΡΡΠ°Π½Π° 300 ΠΌΠ³ Π² ΡΡΡΠΊΠΈ ΠΈ Π°ΡΠΏΠΈΡΠΈΠ½Π° ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ Π΄ΠΎΠ±ΠΈΡΡΡΡ ΡΠ°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΡ ΡΡΠΎΠΌΠ±Π° Π² ΡΡΠΊΠ΅ Π»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ΅Π΄ΡΠ΅ΡΠ΄ΠΈΡ, ΡΠ»ΡΡΡΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΏΠ΅ΡΠ΅ΠΌΠ΅ΠΆΠ°ΡΡΠ΅ΠΉΡΡ Ρ
ΡΠΎΠΌΠΎΡΡ, ΠΈΠ·Π±Π΅ΠΆΠ°ΡΡ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΡ
ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ. COVID-19 ΠΌΠΎΠ³ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΠΎΠ²Π°ΡΡ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ·Π°, Π±ΠΎΠ»Π΅Π΅ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΌΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΠΈΠ±ΡΠΈΠ»Π»ΡΡΠΈΠΈ ΠΏΡΠ΅Π΄ΡΠ΅ΡΠ΄ΠΈΠΉ, ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ², ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½Π°Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ Π½Π΅ ΡΠ²Π»ΡΠ΅ΡΡΡ Π΅Π΄ΠΈΠ½ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΡΠΈΡΠΈΠ½ΠΎΠΉ ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. Π‘OVID-19 Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΏΡΠΈΡΠΈΠ½ΠΎΠΉ ΠΏΡΡΠΌΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΄ΡΠ° ΠΈ ΡΠΎΡΡΠ΄ΠΎΠ², Π½ΠΎ ΠΈ ΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡ ΠΊΠΎΡΠ²Π΅Π½Π½ΠΎΠ΅ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ β ΠΎΡΠ΄Π°Π»ΡΡΡ Π²ΡΡΠ²Π»Π΅Π½ΠΈΠ΅ ΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ Π±ΡΡΡ ΠΏΡΠΈΡΠΈΠ½ΠΎΠΉ Π΅Π΅ Π³ΠΈΠΏΠΎΠ΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΏΠΎΠ΄ ΠΌΠ°ΡΠΊΠΎΠΉ Β«ΠΏΠΎΡΡΠΊΠΎΠ²ΠΈΠ΄Π°Β»
2020 Clinical guidelines for Atrial fibrillation and atrial flutter
Russian Society of Cardiology (RSC).With the participation of Russian Scientific Society of Clinical Electrophysiology, Arrhythmology and Cardiac Pacing, Russian Association of Cardiovascular Surgeons.Approved by the Scientific and Practical Council of the Russian Ministry of Health
HOMOCYSTEINE-LOWERING THERAPY AND LONG-TERM PROGNOSIS AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
Background. Vitamins Π6 Π12 and folic acid (FA) therapy to reduce cardiovascular risk appears to be unreasonable. Negative results of recent large-scale trials might be due to high daily doses of the vitamins and widespread FA fortification programmes. Russian population is known to have high prevalence of FA and vitamin B12 deficiency. Aim. To evaluate the effect of FA, B6 and B12 vitamins (in doses approximate to daily maintenance) on long-term prognosis after elective percutaneous coronary intervention (PCI) in stable ischemic heart disease patients. Material and methods. 264 patients (213 male, age 58.8Β±1.0 years) after successful PCI were involved into the trial. Patients with clinical signs of the vitamins deficiency were not included. Patients were randomly assigned to receive combination of FA (0.6 mg/day), B12 (10 ΞΌg/day), and B6 (4 mg/day) vitamins along with the conventional therapy (n=97) or the conventional therapy only (n=167) for 20 months. The groups were comparable in age, gender and prevalence of coronary risk factors. Composite endpoint was defined as cardiovascular death, acute coronary syndrome, stroke or transient is- chemic attack and need for coronary/carotid revascularization. Results. The vitamins prescription to all of the patients did not reduce composite endpoint incidence according to multivariable regression analysis (RR 0,7; 95%CI 0,4-1,4; p=0,3). Subgroup analysis showed significantly lower composite endpoint incidence in patients who received vitamins and had initially low B12 blood level (<260 pg/ml) as compared to the control group (RR 0.09; 95%CI 0.01-0.9; p=0.04). Conclusion. Treatment with FA, B and B vitamins improves prognosis after PCI in patients with initially low blood vitamin B level